BioCurity Pharmaceuticals Inc. (‘BioCurity’ or ‘Company’) Expanding Patent Portfolio Successes for Supportive Cancer Drugs Designed to Prevent Radiation Therapy Side Effects

BioCurity’s International and US issued patent portfolio in addition to the Company’s pending patent applications provides highly relevant coverage with supporting claims to protect the Company’s proposed clinical efforts.

The Company received issuance of a US patent exclusively licensed from the University of Central Florida Research Foundation and co-owned with the University of Central Florida which covers the use of cerium oxide nanoparticles for the protection of skin or salivary gland for cancer patients undergoing radiation therapy.

Globally, the Company received issuance of the Company’s Australia, Hong Kong and Mexico patents which covers the use of cerium oxide nanoparticles for the reduction of side effects caused by radiation therapy for certain cancer patients receiving a combination of therapeutically effective doses of radiation therapy and chemotherapy as part of their treatment regimen. BioCurity exclusively owns its international patents, which currently exist in Australia, China, Europe, Hong Kong, Japan, and Mexico.

“BioCurity is a global leader in drug development using cerium oxide nanoparticles to mitigate the side effects associated with radiation therapy. The short- and long-term side effects from radiation therapy can impair a cancer patient’s medical treatment plan and can leave cancer survivors with permanent adverse condition. In addition to the healthcare costs of treating radiation therapy side effects for cancer patients, BioCurity’s drugs could eliminate the harmful impact radiation side effects have on patient care,” said Dr. Cheryl Baker, PhD, Scientific Co-Founder, and a Board Member of BioCurity.

About BioCurity Pharmaceuticals Inc.

BioCurity is biotech company with a mission to prevent certain short term and long-term side effects of radiation therapy for cancer patients undergoing radiation therapy. The main goal of radiation therapy is to determine the optimal dose of radiation to the pathological focus with minimal damage to normal tissues located in the area of exposure. The Company’s breakthrough medical discovery was preclinically tested at an MD Anderson Cancer Center affiliate and published in several international scientific articles in peer reviews, highlighting the novel mechanism of action and innovative nanoparticle technology for prevention of radiation damage. BioCurity’s Board of Directors, include BioCurity’s Co-Founder and Executive Chairman Mr. Sam Merchant, BioCurity’s Scientific Founder and Director, Dr. Cheryl Baker, PhD and BioCurity’s Director, Ms. Nancy Cass. BioCurity’s clinical development lead is CSSi LifeSciences, led by Mr. Jim Sergi. BioCurity’s Scientific and Medical Advisor Board include board certified physicians affiliated with top US medical centers of excellence. For more information on BioCurity, management and board members, please visit BioCurity’s website and follow them on LinkedIn, Facebook, Instagram, and Twitter.

This news release contains forward-looking statements, including those relating to the product development of BioCurity Pharmaceuticals Inc. (the “Company” or “BioCurity”), clinical and regulatory timelines, market opportunity and other statements that are predictive in nature, or that depend upon or refer to future events or conditions. Forward-looking statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this news release. BioCurity’s lead product candidate is in preclinical development and is not for sale or use. This news release is not an offer to buy any securities of the Company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005091/en/